ImpriMed: ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market
ImpriMed is a company that provides personalized medicine easily accessible for pets with blood cancer diseases. Pulse 2.0 interviewed ImpriMed CEO and co-founder Sungwon Lim to learn more about the company. The post ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market appeared first on Pulse 2.0.
Read full article »
ImpriMed is a California-based company that provides solutions such as AI-powered personalized drug response prediction and sample analysis for pet owners and veterinarians.
Read more